Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in Spinal Muscular Atrophy (SMA)
NCT02876094Phase 2Terminated
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in spinal muscular atrophy (SMA). Primary endpoint: Peripheral leukocyte SMN protein levels at 6 weeks. Started Jan 2019; status: terminated.
02
Drugs
celecoxib
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02876094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876094.